Clinical trials: Leucovorin
Colorectal Neoplasms
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC).
- Trial name
- NCT01289821
- Testing
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Biliary Tract Cancer, Gallbladder Cancer
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC06 (NCT01926236)
- Testing
- Active Symptom Control, L-folinic acid, 5 FU
- Where
- 17 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- The Christie NHS Foundation Trust
Pancreatic Cancer
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03329248
- Testing
- ALT-803, ETBX-011, GI-4000
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Brain and Central Nervous System Tumors, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416819
- Testing
- filgrastim, rituximab, cytarabine
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Esophageal Squamous Cell Carcinoma
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention…
- Trial name
- NEEDS (NCT04460352)
- Testing
- Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Esophagectomy
- Where
- 12 sites in Canada, Ireland and 3 more
- Volunteers
- 1,020 people
- Sponsor
- Karolinska University Hospital
Childhood Atypical Teratoid/Rhabdoid Tumor
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young…
- Trial name
- NCT00653068
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin
- Where
- 94 sites in United States, Australia and 1 more
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Rectal Cancer
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to…
- Trial name
- GRECCAR12 (NCT02514278)
- Testing
- Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders
- Where
- 29 sites in France
- Volunteers
- 218 people
- Sponsor
- University Hospital, Bordeaux
Colorectal Carcinoma
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV).
- Trial name
- NCT00176774
- Testing
- Irinotecan, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Colorectal Cancer
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
The Nordic FLOX-regime consists of a combination of bolus 5-FU, leukovorin and oxaliplatin (Eloxatin®). Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR).
- Trial name
- NCT00660582
- Testing
- Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 152 people
- Sponsor
- Per Pfeiffer
Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is an investigator-initiated, open-label, single-arm, phase II trial evaluating the efficacy and safety of serplulimab (an anti-PD-1 monoclonal antibody) plus bevacizumab, combined with either FOLFIRINOX or NALIRIFOX…
- Trial name
- NCT07733050
- Testing
- Serplulimab and Bevacizumab injection, FOLFIRINOX/NALIRIFOX, S-1
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai General Hospital, China
Metastatic Colorectal Cancer
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection.
- Trial name
- NCT05103020
- Testing
- intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
ICC
Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis
This study were designed to verify the better method of survival for ICC with distant metastasis. Since the traditional method for ICC with distant metastasis.
- Trial name
- NCT04769908
- Testing
- Systemic Chemotherapy, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Gestational Trophoblastic Neoplasia, Molar Pregnancy
Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia
To evaluate the efficacy and safety of second uterine curettage in patients with low-risk non-metastatic GTN.
- Conditions
- Gestational Trophoblastic Neoplasia, Molar Pregnancy, Gestational Trophoblastic Tumor, Non-Metastatic
- Trial name
- ReCure (NCT04756713)
- Testing
- Uterine curettage, Chemotherapy
- Where
- 7 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Colorectal Cancer, Colorectal Liver Metastases
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or…
- Trial name
- IRIMAD (NCT06501482)
- Testing
- Postoperative reintroduction of FOLFIRI based chemotherapy
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pancreatic Cancer
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
- Trial name
- NCT06151262
- Testing
- Trilaciclib+mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intrahepatic Cholangiocarcinoma
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Southeast Asia and China have the highest incidence of intrahepatic cholangiocarcinoma worldwide, with limited treatment options and large unmet medical needs.
- Trial name
- NCT06375642
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002489
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Combination Chemotherapy in Treating Children With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002590
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 221 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05171166
- Testing
- HAIC, TACE, FOLFOX
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University
Hepatocellular Carcinoma
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular…
- Trial name
- NCT03775395
- Testing
- Lenvatinib, Sorafenib, Hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sun Yat-sen University